Cross-Site Outcome Registry for Deployed Health AI
A shared registry where hospitals pool data to see which health AI tools work best in different settings.
A subscription registry where health systems pool standardized, de-identified outcome data on the AI tools they use, so everyone learns which tools work in which settings — the cross-hospital evidence layer no single site can build alone.
Concept
A benchmarking registry that turns many local AI evaluations into generalizable evidence. Member health systems contribute standardized, de-identified outcome metrics for named categories of deployed tools — sepsis alerts, ambient scribes, diabetic retinopathy screening, scheduling and revenue-cycle automation — through a common data model with federated queries, so patient-level data never leaves the source system. Members receive quarterly benchmark reports showing which tool categories produce outcome gains in which workflow and training contexts (e.g., "ambient scribes cut after-hours documentation time at sites with substantial onboarding, but show no effect where training was minimal"), plus a public scorecard layer that summarizes category-level findings for purchasers and regulators without naming individual sites. The single wedge is generalizability: converting setting-dependent local results into cross-setting knowledge that no single hospital can produce alone.
Why now
The JAMA Summit [0] makes its third priority "creation of a nationally representative data infrastructure and learning environment to support the generation of generalizable knowledge about health effects of AI tools across different settings," precisely because a tool's effects are "highly dependent on the human-computer interface, user training, and setting" — so one site's pilot result cannot be trusted elsewhere. It also notes that many widely adopted tools sit outside FDA oversight, leaving no systematic evidence source at all. Implementation-science work on generative AI in healthcare argues for staged, multi-setting evaluation and governance [2], and the cross-industry policy review shows AI regulatory frameworks proliferating faster than any health-outcome evidence infrastructure [1]. The distributed-data-network model is proven in drug safety, and the raw material — many systems already running scribes, alerts, and imaging AI [0] — now exists to populate it.
Written by GLM · 9 Oct 2026
AI assessment
A high-value infrastructure play that solves the 'generalizability gap' in health AI by aggregating cross-site outcome data, though it faces significant cold-start and data-standardization hurdles.
- Evidence strength 4/5
- The idea directly addresses the specific priority for a 'nationally representative data infrastructure' cited in the JAMA Summit [0] and aligns with implementation science needs for multi-setting evaluation [2].
- Market pull 4/5
- Health systems and GPOs (like Vizient) have a strong financial incentive to know which expensive AI tools actually deliver ROI across different settings.
- Novelty & moat 3/5
- While similar to the 'Rapid Local Effectiveness Trials' idea, it shifts the value proposition from local validation to cross-site benchmarking, creating a network effect moat.
- Feasibility 3/5
- Federated query architectures exist, but the primary challenge is the immense effort required to standardize outcome metrics across disparate EHR implementations.
- Wedge clarity 5/5
- The focus on 'generalizability' as the single wedge is sharp and addresses the exact pain point of current AI procurement.
- Simplicity / focus 4/5
- The product is a focused registry and reporting service rather than a broad AI platform, keeping the scope manageable.
Scored by Gemma 4 · 9 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Coalition for Health AI (CHAI)organization
The nonprofit coalition building assurance standards and a national network for health AI needs exactly this outcome-evidence layer to make its assurances effectiveness-based rather than process-based.
- Peterson Health Technology Instituteorganization
Its mission is evaluating whether digital health tools actually improve care; a federated registry of real-world AI outcomes gives it the multi-site evidence base its reports currently must assemble ad hoc.
- Vizientcompany
The group purchasing organization advises thousands of member hospitals on technology purchasing; category-level outcome benchmarks become a purchasing-decision asset no single member could produce.
- Epic!company
Its Cosmos research database already aggregates de-identified records from hundreds of health systems; adding standardized AI-tool outcome metrics extends it into the evidence infrastructure the field is asking for.
- U.S. Food and Drug Administrationorganization
The agency would gain post-market visibility of cleared AI (imaging, retinopathy screening) and its first systematic window into widely adopted tools outside its oversight — the exact concern the JAMA Summit raises.
Research it builds on
- Generative AI in healthcare: an implementation science informed translational path on application, integration and governanceSandeep Reddy · 2024 · 522 citationsAll ideas from this paper →
- AI, Health, and Health Care Today and TomorrowDerek C. Angus, Rohan Khera, Tracy A. Lieu et al. · 2025 · 181 citationsAll ideas from this paper →
- Policies and regulations of artificial intelligence in healthcare, finance, agriculture, manufacturing, retail, energy, and transportation industryNitin Liladhar Rane, Jayesh Rane, Mallikarjuna Paramesha et al. · 2024 · 21 citationsAll ideas from this paper →